Nabilone & Marijuana Addiction

This study has been completed.
Sponsor:
Information provided by:
University of British Columbia
ClinicalTrials.gov Identifier:
NCT01025700
First received: December 2, 2009
Last updated: February 16, 2011
Last verified: February 2011
  Purpose

Safety of Nabilone in reducing marijuana craving


Condition Intervention Phase
Marijuana Smoking
Drug: Cesemat
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal

Resource links provided by NLM:


Further study details as provided by University of British Columbia:

Primary Outcome Measures:
  • Safety and tolerability to Nabilone [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Marijuana craving questionnaire [ Designated as safety issue: No ]

Estimated Enrollment: 35
Study Start Date: June 2009
Study Completion Date: October 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cesemat Drug: Cesemat
1 mg capsule per day for 21 days
Other Name: Nabilone
No Intervention: Placebo

Detailed Description:

Randomized double blind trial into the safety and efficacy of Cesemat for the treatment of marijuana use

  Eligibility

Ages Eligible for Study:   19 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 19 years or older
  • History of marijuana use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01025700

Locations
Canada, British Columbia
Vancouver General Hospital - Psychiatry Outpatient
Vancouver, British Columbia, Canada
Sponsors and Collaborators
University of British Columbia
Investigators
Principal Investigator: Shaohua Lu, MD University of British Columbia
  More Information

No publications provided

Responsible Party: Shaohua Lu, MD, University of British Columbia
ClinicalTrials.gov Identifier: NCT01025700     History of Changes
Other Study ID Numbers: H08-01999
Study First Received: December 2, 2009
Last Updated: February 16, 2011
Health Authority: Canada: Health Canada

Keywords provided by University of British Columbia:
Efficacy
Marijuana
Reduction
Craving

Additional relevant MeSH terms:
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Nabilone
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Gastrointestinal Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs

ClinicalTrials.gov processed this record on September 30, 2014